Pemphigoid is a rare autoimmune blistering disease that mainly affects people over the age of 60, causing large, fluid-filled blisters on the skin and sometimes inside the mouth. While the condition can be challenging to live with, modern treatment approaches can control symptoms effectively, helping patients manage the disease and maintain their quality of life.

Understanding Treatment Goals for Pemphigoid

When someone is diagnosed with pemphigoid, the primary focus of treatment is to bring the disease under control and help patients return to a more comfortable daily life. Treatment aims to heal existing blisters, stop new ones from forming, and relieve the intense itching that often accompanies this condition. The approach taken depends on how widespread the blisters are, where they appear on the body, and the overall health of the patient.^[1][2]

Unlike some conditions that can be cured completely, pemphigoid is a chronic disease that requires ongoing management. However, many patients experience periods where the disease becomes less active or even goes into remission. Some people find that their pemphigoid resolves on its own after one to five years, though this timeline varies considerably from person to person. During active phases of the disease, the goal is to use the lowest possible dose of medication to keep symptoms under control while minimizing the risk of side effects.^[5][7]

Medical societies have established guidelines for treating pemphigoid based on decades of clinical experience and research. These standard treatments have been tested and proven effective in large groups of patients. At the same time, researchers continue to explore new therapies through clinical trials, offering hope for treatments that may work better or cause fewer side effects. The combination of established treatments and ongoing research means that patients today have more options than ever before.^[4]

Standard Treatment Approaches

The cornerstone of pemphigoid treatment involves medications called corticosteroids, which are powerful anti-inflammatory drugs that suppress the immune system’s attack on the skin. These medications work by reducing the inflammation that causes blisters to form. Corticosteroids can be applied directly to the skin as creams or ointments, or taken by mouth as tablets, depending on how severe and widespread the blistering is.^[10][12]

For patients with blisters limited to small areas of skin, doctors typically start with topical corticosteroid creams. The most commonly prescribed is clobetasol propionate, a very strong steroid cream that patients apply directly to affected areas. This approach has been shown in studies to be not only effective but also safer than oral steroids, particularly for elderly patients who may have other health conditions. Topical steroids work by penetrating the skin and reducing the immune response at the site of blistering. While they can cause side effects such as skin thinning with long-term use, these risks are generally lower than those associated with steroids taken by mouth.^[5][10]

When blistering is more extensive or covers large areas of the body, oral corticosteroids become necessary. Prednisone is the most frequently used oral steroid for pemphigoid. These medications work throughout the entire body to calm the overactive immune response. Doctors typically start with higher doses to bring the disease under control quickly, then gradually reduce the dose over several weeks or months. This tapering process is important because suddenly stopping steroids can cause the disease to flare up again and can also affect the body’s natural production of hormones.^[4][21]

To reduce dependence on steroids and their associated risks, doctors often add steroid-sparing agents. These are medications that help control the immune system through different mechanisms, allowing patients to take lower doses of steroids or stop them entirely. Azathioprine is one such medication that works by suppressing the production of certain immune cells. It can take several weeks to become fully effective, so it’s typically started while the patient is still taking steroids. Mycophenolate mofetil is another immunosuppressant that has become increasingly popular because it tends to be well-tolerated and effective for pemphigoid patients.^[5][10]

Some patients respond well to antibiotics that have anti-inflammatory properties beyond their ability to fight bacteria. Doxycycline and dapsone fall into this category. While these medications are traditionally used to treat bacterial infections, they also have effects on the immune system that can help control pemphigoid. Doxycycline is particularly useful because it has a good safety profile, even for older patients. Dapsone works by interfering with the inflammatory cells that contribute to blister formation. However, dapsone requires careful monitoring because it can affect red blood cells in some people, particularly those with certain enzyme deficiencies.^[10][15]

The duration of treatment varies greatly among patients. Some people can gradually stop their medications after a few months once the disease is well-controlled. Others need to continue with lower maintenance doses for several years to prevent flare-ups. Regular follow-up appointments are essential so doctors can monitor the disease activity and adjust medications as needed. During these visits, doctors also watch for signs of infection in open blisters and check for medication side effects through physical examinations and blood tests.^[4][7]

For patients who have blisters in their mouth, treatment includes special mouthwashes containing combinations of medications to reduce pain, inflammation, and the risk of infection. These “magic mouthwashes” typically contain a steroid to reduce inflammation, a local anesthetic to numb the pain, and sometimes an antacid to help the mixture coat the mouth surfaces. Patients are advised to avoid spicy, acidic, or salty foods that can irritate mouth sores, and to maintain gentle oral hygiene with soft toothbrushes.^[5][22]

Innovative Treatments Being Studied in Clinical Trials

Beyond standard treatments, researchers are actively investigating new therapeutic approaches for pemphigoid through clinical trials. These studies are essential for discovering treatments that may work better, cause fewer side effects, or help patients who don’t respond well to current therapies. Clinical trials typically progress through three phases: Phase I focuses on safety and determining appropriate doses in small groups of people; Phase II examines whether the treatment is effective and continues to monitor safety in larger groups; and Phase III compares the new treatment with standard therapies in even larger patient populations.^[14]

Rituximab represents one of the most promising advances in pemphigoid treatment. This medication is a type of biologic therapy that specifically targets B cells, which are the immune cells responsible for producing the harmful antibodies that attack the skin in pemphigoid. Rituximab works by attaching to a protein called CD20 found on the surface of B cells, marking them for destruction by the immune system. By reducing the number of B cells, rituximab decreases the production of the antibodies that cause blistering.^[14]

Studies have shown that rituximab can induce remission in patients with severe pemphigoid who haven’t responded well to conventional treatments. In clinical observations, some patients achieved complete clearing of their blisters and were able to stop or significantly reduce their steroid medications. However, rituximab is not without risks. Because it suppresses a key part of the immune system, it increases the risk of infections. Patients taking rituximab require close monitoring and may need to avoid crowds or people who are sick. Despite these concerns, many doctors consider rituximab an important option for patients with severe, difficult-to-control disease.^[14][15]

Dupilumab is another biologic medication that has shown remarkable promise in clinical trials for bullous pemphigoid. This drug works by blocking interleukin-4 and interleukin-13, which are proteins that play important roles in the inflammatory response. By interfering with these signaling molecules, dupilumab reduces inflammation without broadly suppressing the entire immune system. Clinical studies have reported that 87 to 92 percent of pemphigoid patients achieved good disease control with dupilumab. Particularly impressive was how quickly patients experienced relief from the intense itching that often accompanies pemphigoid, sometimes within days of starting treatment.^[14][15]

What makes dupilumab especially attractive is its safety profile. Because it targets specific inflammatory pathways rather than shutting down broad immune functions, it appears to cause fewer serious side effects than traditional immunosuppressants. This makes it particularly suitable for elderly or frail patients who may not tolerate stronger medications well. Some researchers believe dupilumab could eventually become a first-line treatment option, meaning it might be used earlier in the disease course rather than being reserved only for severe cases.^[14][15]

Omalizumab offers yet another approach by targeting immunoglobulin E (IgE), a type of antibody involved in allergic reactions and also implicated in some cases of pemphigoid. Omalizumab binds to IgE in the bloodstream, preventing it from attaching to cells and triggering inflammation. Clinical trials have demonstrated that omalizumab can effectively control pemphigoid symptoms while allowing patients to reduce their steroid doses. The medication is given as an injection under the skin, typically every two to four weeks. While some patients experience disease recurrence after stopping omalizumab, many achieve good control while on the medication.^[14][15]

Researchers are also exploring intravenous immunoglobulin (IVIG) therapy for pemphigoid. IVIG consists of antibodies pooled from thousands of healthy blood donors. When given to pemphigoid patients, these antibodies appear to modulate the immune system in ways that reduce the production of the harmful antibodies causing blisters. IVIG is generally well-tolerated and can be particularly useful for patients who cannot take other immunosuppressant medications due to infections or other health concerns. However, IVIG is expensive and requires regular infusions, typically given monthly.^[10][15]

Beyond these established investigational therapies, scientists are studying several novel approaches. Janus kinase (JAK) inhibitors represent a newer class of medications that block specific enzymes involved in the inflammatory signaling pathways. Early reports suggest these medications might be effective for pemphigoid, though more research is needed to establish their safety and effectiveness. Another experimental approach involves a medication called efgartigimod, which targets a specific receptor that influences how long harmful antibodies remain in the bloodstream. By enhancing the removal of these antibodies, efgartigimod might reduce disease activity.^[15]

Some clinical trials are examining combination approaches, such as using rituximab together with IVIG or pairing biologic medications with low-dose steroids. The idea behind combination therapy is that attacking the disease through multiple mechanisms might achieve better control while minimizing the dose and duration of any single medication. Preliminary results have been encouraging, but larger studies are needed to determine the optimal combinations and sequences of treatments.^[15]

Clinical trials for pemphigoid are conducted at medical centers around the world, including in the United States, Europe, and other regions. Eligibility for trials typically depends on factors such as disease severity, previous treatments tried, overall health status, and sometimes specific characteristics of the disease or immune markers. Patients interested in participating in clinical trials should discuss options with their dermatologist, who can help determine if any suitable studies are available and whether participation might be beneficial.^[14]

Most Common Treatment Methods

• Corticosteroids
  • Topical corticosteroid creams such as clobetasol propionate applied directly to affected skin areas
  • Oral corticosteroids like prednisone for more widespread disease, starting with higher doses and gradually tapering
  • Work by suppressing immune system inflammation that causes blister formation
• Immunosuppressant Medications
  • Azathioprine to suppress immune cell production and reduce antibody formation
  • Mycophenolate mofetil as a steroid-sparing agent with generally good tolerability
  • Methotrexate for patients who need alternatives to other immunosuppressants
  • Used to allow reduction in steroid doses and minimize long-term steroid side effects
• Antibiotic and Anti-inflammatory Therapies
  • Doxycycline providing both anti-inflammatory effects and infection prevention
  • Dapsone interfering with inflammatory cell activity to control blister formation
  • Tetracycline antibiotics offering anti-inflammatory properties beyond bacterial control
• Biologic Therapies
  • Rituximab targeting CD20 on B cells to reduce harmful antibody production
  • Dupilumab blocking interleukin-4 and interleukin-13 inflammatory pathways
  • Omalizumab targeting IgE antibodies involved in some pemphigoid cases
  • Generally reserved for severe or treatment-resistant disease
• Intravenous Immunoglobulin (IVIG)
  • Pooled antibodies from healthy donors given by infusion
  • Modulates immune system to reduce harmful antibody production
  • Option for patients who cannot tolerate traditional immunosuppressants
• Supportive Care and Symptom Management
  • Specialized mouthwashes containing steroids, anesthetics, and antacids for oral blisters
  • Proper wound care and dressing techniques to prevent infection
  • Pain management medications when needed
  • Medications to protect bones and stomach during steroid treatment